Title: Hybrid/Decentralized Trials: Operationalizing for Success Today and Planning for the Future
Date: Sunday, April 24, 2022
Time: 3:15 – 4:15 p.m. ET
Join experts in Wearables and Digital Biomarkers and electronic Clinical Outcome Assessment (eCOA) to hear lessons learned from hybrid/decentralized trials with multiple clinical outcome endpoints. Clinical research professionals across disciplines and roles will gain an understanding of the landscape of clinical trials and strategies to prepare for the operation of successful decentralized trials that have a unified experience for both patients and clinical staff. The concepts and examples shared will aid in professional and career development as attendees will be able to navigate future evolution of this space, including regulatory approval of digital endpoints and patient-focused drug development.
Principal Scientific Advisor at Clario
Dr. Hughes is a scientist with over 15 years of experience in behavioral and life sciences, focusing particularly on the role of human behavior in optimizing health outcomes through prevention, care, and treatment. She is currently a Principal Scientific Advisor at Clario, a global data and technology company that helps to minimize risk in clinical trials. She provides dedicated support to a number of pharmaceutical company sponsors and is the subject matter expert for vaccines and infectious diseases. She has taught courses at the CDC, USAID, and has held international workshops on these issues in more than a dozen countries.
Vice President, Wearables/Digital Biomarkers at Clario
Matthew Johnson is a digital technology leader driven to improve healthcare delivery through advances in technology. He served as the General Manager and Chief Commercial Officer at APDM Wearable Technologies when it was acquired by Clario in June of 2020. His current strategic interest is improving clinical trials by developing and introducing the next generation of scientifically validated digital endpoints. His next initiative will be coupling these digital technologies and endpoints to therapeutics to enable precision medicine on a global scale.